Author response: Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease

We appreciate the comments from Drs. Scherzer, Riise, and Locascio on our article1 on the effects of β2-adrenoceptor (β2AR) antagonists and agonists and risk of Parkinson disease (PD). Since the initial publication,2 this hypothesis has been scrutinized by multiple groups, yielding conflicting results.2–5